Paul Maurin advises on French and cross-border aspects of the Firm's capital markets, mergers and acquisitions (public and private M&A), and venture capital transactions.
He assists companies with strong growth potential, whether listed or unlisted, as well as their executive, industrial, and financial shareholders. He is particularly active in the new technologies (Contentsquare, Doctolib, Ledger, Agicap) and the sectors of biotech/medtech (Adocia, Carmat, Cellectis, Nanobiotix, Median Technologies) and renewable energies (Arverne Group, Voltalia). He assists these companies throughout their development, from their creation to their sale or IPO. Paul also regularly advises listed companies on fundraising, financial communications, governance, and executive compensation.
His recent and representative transactions include the IPOs in France of Deezer, Arverne Group (in both cases via a SPAC [special purpose acquisition company]), Tikehau Capital, and Voltalia, as well as Nanobiotix in the United States; fundraising for private companies (Agicap, Doctolib, Ekimetrics, Ledger, ManoMano) and issuers listed on Euronext (Adocia, Carmat, Voltalia) or Nasdaq (Cellectis, Nanobiotix); the sales of Amolyt to AstraZeneca, Silicon Mobility to Intel, and Zelros to Earnix; as well as the acquisition of the Magimix group by Lavafields.
Experience
- King's College London (LL.M. in International Financial Law with honors 2013); E.S.S.E.C. (Advanced Master in Management and International Business Law 2012); French Bar School of Paris (CAPA 2011); University of Aix Marseille (Advanced Master in International Business Law with honors 2008; D.J.C.E. [Diploma in Legal Practice] with honors 2008)
- Paris
- English, French